Impact of cross-reference pricing on pharmaceutical prices: Manufacturers' pricing strategies and price regulation

Applied Health Economics and Health Policy

Volumn 5, Issue 4, 2006, Pages 235-247

  Stargardt, Tom ^a   Schreyögg, Jonas ^a  

^a TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUSTRIA; COST MINIMIZATION ANALYSIS; DRUG COST; EUROPE; GERMANY; HEALTH CARE SYSTEM; IRELAND; MARKETING; PORTUGAL; PROSPECTIVE PRICING; QUANTITATIVE ANALYSIS; REIMBURSEMENT; THEORETICAL STUDY; COMMERCIAL PHENOMENA; ECONOMICS; GOVERNMENT REGULATION; ORGANIZATION AND MANAGEMENT; PHARMACOECONOMICS;

DRUG;

COMMERCE; ECONOMICS, PHARMACEUTICAL; GERMANY; GOVERNMENT REGULATION; PHARMACEUTICAL PREPARATIONS; REIMBURSEMENT MECHANISMS;

EID: 34047102353     PISSN: 11755652     EISSN: 11755652     Source Type: Journal    
DOI: 10.2165/00148365-200605040-00005     Document Type: Article

References (36)

1. Kanavos P, Mossialos E. Outstanding regulatory aspects in the European pharmaceutical market. Pharmacoeconomics 1999; 15 (6): 519-33
2. Giuliani G, Selke G, Garattini L. The German experience in reference pricing. Health Policy 1998; 44 (1): 73-85
3. López-Casasnovas G, Puig-Junoy J. Review of the literature on reference pricing. In: López-Casasnovas G, Jönsson B, editors. Reference pricing and pharmaceutical policy. Barcelona: Springer; 2001: 1-41
4. Rosian I, Habl C, Vogler S, et al. Arzneimittelausgaben - Strategien zur Kostendämpfung in der Europäischen Union. Wien: Österreichisches Bundesinstitut für Gesundheitswesen, 2001
5. Mrazek MF, Mossialos E. Regulating pharmaceutical prices in the European Union. In: Mossialos E, Mrazek MF, Walley T, editors. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Cornwall: WHO on behalf of the European Observatory on Health Care Systems and Policies; 2004: 114-29
6. Stargardt T, Schreyögg J, Busse R. Arzneimittelfestbeträge: gruppenbildung, preisberechnung mittels regressionsverfahren und wirkungen. Das Gesundheitswesen 2005; 67 (7): 468-77
7. Walley T, Mrazek MF, Mossialos E. Regulating pharmaceutical markets: improving efficiency and controlling costs in the UK. Int J of Health Plann Manage 2005; 20 (4): 375-98
8. Maynard A, Bloor K. Dilemmas in regulation of the market for pharmaceuticals. Health Aff 2003; 22 (3): 31-41
9. Simoens S, De Bruyn K, Bogaert M, et al. Pharmaceutical policy regarding generic drugs in Belgium. Pharmacoeconomics 2005; 23 (8): 755-66
10. Vuorenkoski L, Toivininen H, Hemminki E. Drug reimbursement in Finland: a case of explicit prioritising in special categories. Health Policy 2003; 66 (2): 169-77
11. Anell A. Priority setting for pharmaceuticals: the use of health economic evidence by reimbursement and clinical guidance committees. Eur J Health Econ 2004; 5 (1): 28-35
12. Paris V. Pharmaceutical regulation in France. Int J Health Plann Manage 2005; 20 (4): 307-28
13. Anell A, Persson U. Reimbursement and clinical guidance for pharmaceuticals in Sweden. Eur J Health Econ 2005; 6 (3): 274-9
14. Vogler S, Habl C. Arzneimittel - distribution in Skandinavien. Wien: Österreichisches Bundesinstitut für Gesundheitswesen, 2003
15. Mossialos E, Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. Int J Health Plann Manage 2005; 20 (4): 291-306
16. Martin DK, Giacomini M, Singer PA. Fairness, accountability for reasonableness, and the views of priority setting decision-makers. Health Policy 2002; 61: 279-90
17. Pedersen K. Pricing and reimbursement of drugs in Denmark. Eur J Health Econ 2003; 4 (1): 60-5
18. Danish Medicines Agency. European prices [online]. Available from URL: http://www.dkma.dk/1024/visUKLSArtikel.asp?.artikelID=3177 [Accessed 2006 Feb 14]
19. Kontozamanis V, Mantzouneas E, Stoforos C. An overview of the Greek pharmaceutical market. Eur J Health Econ 2005; 4 (4): 327-33
20. US Department of Commerce International Trade Administration. Pharmaceutical price controls in OECD countries: implications for U.S. consumers, pricing, research and development, and innovation. Washington, DC: US Department of Commerce International Trade Administration, 2004 [online]. Available from URL: http://www.ita.doc.gov/td/chemicals/drugpricingstudy.pdf [Accessed 2006 Dec 21]
21. Mossialos E, Allin S, Karras K, et al. An investigation of Caesarean sections in three Greek hospitals: the impact of financial incentives and convenience. Eur J Public Health 2005; 15 (3): 288-95
22. Gouveua Pinto C, Teixeira I. Pricing and reimbursement of pharmaceuticals in Portugal. Eur J Health Econ 2002; 3: 267-70
23. Bentes M, Dias CM, Sakellarides C, et al. Health care systems in transition: Portugal. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies, 2004
24. Barry M, Lesley T, Ryan M. Pricing and reimbursement of drugs in Ireland. Eur J Health Econ 2004; 5 (2): 190-4
25. Euro-Med-Stat Working Group on Pharmaceutical Price Indicators. The Library of European Union Pharmaceutical Indicators: price indicators. 2004 [online]. Available from URL: http://www.euromedstat.cnr.it/indicators/ indicators.asp [Accessed 2006 Dec 22]
26. Danzon PM. Reference pricing: theory and evidence. In: López-Casasnovas G, Jönsson B, editors. Reference pricing and pharmaceutical policy. Barcelona: Springer; 2005: 86-126
27. de Wolf P, Brouwer W, Rutten F. Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs? Int J Health Plann Manage 2005; 20 (4): 351-74
28. Chefärztliche Dienststelle der Niederösterreichischen Gebietskrankenkasse, 2004. Neuerungen im Medikamentenbereich ab 1. 1. 2005 [online]. Available from URL: http://www.noegkk.at/mediaDB/80442.PDF [Accessed 2007 Jan 3]
29. Bundesministerium für Gesundheit und Frauen. Regelung für die Vorgehensweise der Preiskommission bei der Erteilung des EU-Durschnittspreises gemäβ§ 351c Abs. 6 ASVG, zuletzt geändert am 29. 4. 2005 [online]. Available from URL: http://www.bmgf.gv.at/cms/site/detail.htm?.thema= CH0008&doc=CMS1078931881119 [Accessed 2005 Aug 28]
30. OECD. OECD Health Data, 2005 [Database]
31. Ghislandi S, Krulichova I, Garattini L. Pharmaceutical policy in Italy: towards a structural change? Health Policy 2005; 72 (1): 53-63
32. VFA (Verband Forschender Arzneimittelhersteller). Statistics 2005. Berlin: VFA, 2005
33. Busse R, Schreyögg J, Henke K-D. Pharmaceutical regulation in Germany: improving efficiency and controlling expenditures. Int J Health Plann Manage 2005; 20 (4): 329-49
34. Schreyögg J, Busse R. Drug budgets and effects on physicians' prescription behaviour: new evidence from Germany. J Pharm Finance Econ Policy 2005; 14 (3): 77-95
35. Danzon PM, Chao L. Cross-national price differences for pharmaceuticals: how large, and why? Health Econ 2000; 19: 159-95
36. Puig-Junoy J. What is required to evaluate the impact of pharmaceutical reference pricing? Appl Health Econ Health Policy 2005; 4 (2): 87-98